BenevolentAI
ben phase progressing phase double blind placebo controlled in patient two part clinical study day day day day active recruiting sites in the in a further sites under approval recruitment completion anticipated our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved our intention is to out development and of ben following completion of this trial with key big and dermatology specialists as potential part | BenevolentAI
Company
Deck Type
Deck date
September 2022
Slide
49 of 74
Similar slides by BenevolentAI
Investor Presentation
October 2022
Related slides by other companies
Investor Day
January 2022
Investor Presentation
August 2023
Investor Presentation
August 2023
Investor Presentation
May 2023
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io